Hepatitis C infection seroprevalence in pregnant women worldwide: a systematic review and meta-analysis

Abbasi, Farzaneh; Almukhtar, Mustafa; Fazlollahpour-Naghibi, Andarz; Alizadeh, Faezeh; Behzad Moghadam, Kimia; Jafari Tadi, Mehrdad; Ghadimi, Saleh; Bagheri, Kimia; Babaei, Hedye; Bijani, Mohammad Hossein; Rouholamin, Safoura; Razavi, Maryam; Rezaeinejad, Mahroo; Chemaitelly, Hiam; Sepidarkish, Mahdi; Farid-Mojtahedi, Maryam; Rostami, Ali

doi:10.1016/j.eclinm.2023.102327

Cited by 5 publications

(1 citation statement)

References 77 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In recent years, an increase in the number of hepatitis C virus (HCV) infections has been observed among young women, in particular due to the intravenous use of psychoactive substances, piercing procedures and tattooing. 1,2 According to the Centers for Disease Control and Prevention (CDC) (USA), the national rate of HCV infection among women giving birth in the U.S. increased by more than 400% from 0.8 per 1000 deliveries in 2000 to 4.1 in 2015. Rates were much higher (87.4 and 216.9/1000 deliveries, respectively) among women with a history of opioid use disorder, but an increase from 0.7 to 2.6/1000 deliveries was also observed in women who did not use opioids in the past.…”

Section: Introductionmentioning

confidence: 99%

Direct‐acting antivirals in women of reproductive age infected with hepatitis C virus

Dobrowolska,

Pawłowska,

Zarębska‐Michaluk

et al. 2024

Journal of Viral Hepatitis

View full text Add to dashboard Cite

Eliminating hepatitis C virus (HCV) infection in the population of women of reproductive age is important not only for the health of women themselves but also for the health of newborns. This study aimed to evaluate the implementation of this goal by analysing the effectiveness of contemporary therapy in a large cohort from everyday clinical practice along with identifying factors reducing therapeutic success. The analysed population consisted of 7861 patients, including 3388 women aged 15–49, treated in 2015–2022 in 26 hepatology centres. Data were collected retrospectively using a nationwide EpiTer‐2 database. Females were significantly less often infected with HCV genotype 3 compared to males (11.2% vs. 15.7%) and less frequently showed comorbidities (40.5% vs. 44.2%) and comedications (37.2% vs. 45.2%). Hepatocellular carcinoma, liver transplantation, HIV and HBV coinfections were reported significantly less frequently in women. Regardless of the treatment type, females significantly more often reached sustained virologic response (98.8%) compared to males (96.8%). Regardless of gender, genotype 3 and cirrhosis were independent factors increasing the risk of treatment failure. Women more commonly reported adverse events, but death occurred significantly more frequently in men (0.3% vs. 0.1%), usually related to underlying advanced liver disease. We have demonstrated excellent effectiveness and safety profiles for treating HCV infection in women. This gives hope for the micro‐elimination of HCV infections in women, translating into a reduced risk of severe disease in both women and their children.

show abstract

Section: Introductionmentioning

confidence: 99%